Introduction {#S1}
============

Vasoactive intestinal peptide (VIP), a 28 amino-acid residue peptide originally isolated from porcine duodenum by [@B80], owes its name to its powerful ability to cause vasodilatation ([@B84]), by promoting vascular smooth muscle relaxation in the gastrointestinal tract when released by peripheral nerves of the sympathetic nervous system ([@B85]). In subsequent years, VIP was described in multiple peripheral and central neuronal control systems, where it acts as neurotransmitter, neurotrophic or neuroprotective factor ([@B11]; [@B33]). Discovery of pituitary adenylate cyclase-activating polypeptide (PACAP) in the ovine hypothalamus ([@B78]), where it acts as an endocrine regulator, brought additional complexity to the understanding of the actions of VIP, since these two peptides share common receptors and are often present together in the same brain regions (see below). The actions of PACAP on synaptic transmission, plasticity and cognition are reviewed in another paper in this research topic ([@B17]) and will be discussed here only when clarifying the duality of VIP vs. PACAP signaling. VIP is nowadays recognized as an important modulator of synaptic transmission and plasticity, network excitability as well as of learning and memory processes and has been associated with cognitive deficits in several central nervous system (CNS) diseases. This paper reviews the multiple roles of VIP in synaptic transmission, synaptic plasticity and hippocampal-dependent learning and memory processes, the role of VIP in hippocampal and cognitive disfunction in mesial temporal lobe epilepsy (MTLE) and the therapeutic opportunities that this presents.

VIP in the Hippocampus {#S2}
======================

Upon its discovery, VIP expression was reported in the human hippocampus and the hippocampus of animal models ([@B38]; [@B74]; [@B9]), where VIP was also shown to bind to hippocampal membranes ([@B92]; [@B9]). Shortly after, it became evident that VIP expression was predominant in hippocampal GABAergic interneurons ([@B67], [@B68]; [@B73]; [@B69]) and that modulation of GABAergic transmission was likely an important target for VIP action. VIP was also early recognized to have a crucial role in mnemonic processes and particularly in hippocampal-dependent memory traits ([@B21]; [@B40]; [@B45]). Nevertheless, the first report of its physiological actions in the CNS described VIP excitation of hippocampal CA1 neurones ([@B35]). This enhancement in pyramidal cell excitability was latter shown to occur essentially through reduction of the Ca^2+^- and cAMP-dependent K^+^-conductance, leading to a decrease of the long-lasting afterhyperpolarization (sAHP) and a reduction of the accommodation of firing ([@B50]). This action was postsynaptic since it prevailed in low Ca^2+^ -- high Mg^2+^ medium and was later demonstrated to depend on protein kinase A (PKA) activity ([@B54]). Later, the actions of VIP on hippocampal GABAergic transmission were described showing that VIP increases the frequency of miniature IPSCs in cultured pyramidal neurones without affecting their amplitude ([@B100]), which suggests a presynaptic facilitation of GABA release by VIP. This appeared contradictory since VIP actions would lead to opposing effects on pyramidal cell excitability. All these findings are summarized in [Table 1](#T1){ref-type="table"}. When the anatomy of VIP-expressing interneurons (*VIP^+^ INs*) in the hippocampus was elucidated ([@B1], [@B2]; [@B51]) the different roles of VIP in modulation of hippocampal GABAergic transmission and regulation of pyramidal cell excitability began to be clarified.

###### 

Effects of VIP on hippocampal excitatory and inhibitory networks and VIP receptors involved.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Action                                                                                                          Target                          Receptor                        Species/preparation                                                                      References
  --------------------------------------------------------------------------------------------------------------- ------------------------------- ------------------------------- ---------------------------------------------------------------------------------------- ------------
  Enhanced pyramidal cell excitability                                                                            CA1 PNs                         Unknown                         Rat hippocampal slices                                                                   [@B35]

  Enhanced synaptic transmission and pyramidal cell excitability and;\                                            CA1 PNs                         Unknown                         Male Wistar rats (young adult): hippocampal slices                                       [@B50]
  Reduced the slow afterhyperpolarization (Ca^2+^-dependent K^+^ current)                                                                                                                                                                                                  

  VIP application to the *O/A* in the absence of synaptic interactions, increased the firing rate O/A INs and;\   CA1 INs and PNs                 Unknown                         Male NMRI mice (young adult): hippocampal slices                                         [@B105]
  Decreased fEPSP slope rat the *SR* and *SLM*,                                                                                                                                                                                                                            

  Increased the frequency of mIPSCs without affecting their mean magnitude                                        Hippocampal neurons             Unknown                         Cultured hippocampal neurons                                                             [@B100]

  Enhanced EPSCs                                                                                                  CA1 PNs                         Unknown                         Juvenile male Wistar rats: hippocampal slices                                            [@B16]

  Enhanced synaptic transmission through disinhibition and pyramidal cell excitability\                           CA1 PNs (dendrites and soma)\   Unknown                         Male Wistar rats (young adult): hippocampal slices                                       [@B29]
  Enhanced GABAergic currents\                                                                                    CA1 INs and PNs\                                                                                                                                         
  Enhanced GABA release                                                                                           GABAergic nerve terminals                                                                                                                                

  VIP enhanced synaptic transmission                                                                              CA1 PNs (dendrites)             VPAC~1~ and VPAC~2~ receptors   Male Wistar rats (young adult): hippocampal slices                                       [@B26]

  Enhances pyramidal cell excitability                                                                            CA1 PNs                         VPAC~2~ receptor                Male Wistar rats (young adult): hippocampal slices                                       [@B27]

  VIP enhanced the amplitude of NMDARs                                                                            CA1 PNs                         VPAC~1~/VPAC~2~ receptors       Juvenile and young adult male wistar rats: isolated CA1 neurons and hippocampal slices   [@B104]

  Endogenous VIP inhibits CA1 hippocampal LTP                                                                     CA1 PNs (dendrites)             VPAC~1~ receptor                Male Wistar rats (young adult): hippocampal slices                                       [@B28]

  Endogenous VIP inhibits hippocampal CA1 LTD and depotentiation                                                  CA1 PNs (dendrites)             VPAC~1~ receptor                Juvenile and young adult male Wistar rats: hippocampal slices                            [@B23]

  Enhances exocytotic GABA release and\                                                                           GABAergic nerve terminals       VPAC~2~ receptor\               Male Wistar rats (young adult): isolated nerve terminals                                 [@B25]
  GAT-1 nerve terminal reversal\                                                                                                                  \                                                                                                                        
  Inhibits exocytotic GABA release                                                                                                                VPAC~1~ receptor                                                                                                         
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CA1, hippocampus Cornus Ammonis 1; GAT-1, GABA transporter 1; INs, interneurons; NMRI, Naval Medical Research Institute; O/A, hippocampal Oriens-Alveus layer; PNs, Pyramidal neurons; SR, Stratum radiatum; SLM, Stratum lacunosum-moleculare; VPAC
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and VPAC

2

, VIP -- Vasoactive intestinal peptide; VIP receptors 1 and 2.

Detailed immunohistochemistry studies fully characterized hippocampal *VIP^+^ INs* dendritic trees and axon projections ([@B1], [@B2]), allowing the classification of *VIP^+^ INs* into two fundamental groups according to their targets: *VIP^+^ basket cells* are responsible for somatic inhibition of pyramidal cells, are also immunoreactive for cholecystokinin (*VIP^+^-CCK^+^ BCs*, [Figure 1](#F1){ref-type="fig"}) and do not express parvalbumin, as most *BCs* in the hippocampus. *VIP*^+^ *INs* that selectively innervate other interneurons (*VIP*^+^ *IS INs*) include two subtypes: (a) interneurons with cell bodies located at the *stratum pyramidale (SP)* or near and projecting to the *stratum Oriens/Alveus* border (*VIP*^+^ *IS O/A INs* or type III IS cells, [Figure 1](#F1){ref-type="fig"}), that also express the interneuron marker calretinin and target mostly somatostatin-expressing (SOM^+^) *oriens lacunosum-moleculare* (*OLM*) interneurons innervating the distal dendrites of pyramidal cells at the *stratum lacunosum-moleculare (SLM)* and (b) *VIP*^+^ *INs* that project their axons to the *stratum radiatum* (*SR*, *VIP^+^ IS SR INs* or type II IS cells, [Figure 1](#F1){ref-type="fig"}), with cell bodies located either at the *SR/SLM* border or at *SR/SP* and targeting *interneurons* controlling synaptic transmission to proximal dendrites of pyramidal cells in the *SR* ([@B1], [@B2]; [@B66]). In genetically modified VIP-eGFP mice, additional targets of *VIP^+^ IS O/A INs* in the *O/A*, including bistratified cells and oriens--oriens INs, have been described and recently a new VIP expressing interneuron population located at the O/A (*VIP*^+^ long-range projecting INs, *VIP*^+^ *LRP INs*) was described targeting *INs* within the O/A in CA1 but also both *INs* and pyramidal cells within the *subiculum* ([@B42]). It is not clear if it is also present in the rat hippocampus.

![Representation of VIP-containing interneurons in the rat hippocampus: layer location and target selectivity. PN, pyramidal neuron (triangle, light blue); Interneurons (circles, pink); VIP-containing interneurons (circles, blue); *VIP^+^-CCK^+^ BCs*: VIP-containing *basket cells*; *VIP^+^ IS O/A IN*: VIP-containing interneuron-selective interneuron targeting the *stratum oriens*/*Alveus* and *VIP^+^ IS SR IN*: VIP-containing interneuron-selective interneuron targeting the *stratum radiatum*; OLM IN -- *Stratum oriens* interneuron projecting to the *Stratum lacunosum-moleculare*; SR IN -- *Stratum radiatum* local interneurons. Str.: *stratum.*](fncel-14-00153-g001){#F1}

Considering the early acquired knowledge ([@B1], [@B2]) on the target selectivity of VIP-IS hippocampal interneurons in the rat, [@B105] studied the influence of VIP application to the *Oriens/Alveus* border and showed that in the absence of synaptic interactions, VIP increased the firing rate of these interneurons and decreased the slope of the fEPSPs recorded at the *SR* and *SLM*, thus decreasing excitatory synaptic transmission through an increase in inhibitory transmission ([@B105]). These mechanisms could not account for the previously observed increase in synaptic transmission and pyramidal cell firing ([@B50]). In fact, VIP-mediated concomitant pre and post-synaptic enhancement of GABAergic transmission generating disinhibition of synaptic transmission to pyramidal cell dendrites ([@B29]) appears to coexist with direct VIP mediated actions on pyramidal cell bodies either promoting enhancement glutamatergic EPSCs ([@B16]) or GABAergic currents ([@B29]) in rat hippocampal slices. The physiological relevance of these conflicting observations remains poorly understood but may be relevant in distinct physiological conditions, depending on network and behavioral state-dependent activation of different interneuron populations ([@B96]; [@B5]; [@B42]; [@B95]; [@B75]).

VIP and VIP Receptors {#S3}
=====================

VIP shows structural similarity to other neuroendocrine peptides, including secretin, glucagon, gastric inhibitory peptide, growth hormone releasing factor and PACAP ([@B33]); and belongs glucagon--secretin--VIP family of peptides targets ([@B18]). VIP acts trough two high affinity receptors (VPAC~1~ and VPAC~2~) that belong to Group II receptor (GPCR) family and are encoded by two different genes sharing only 55% similarity. These have nearly the same affinity for VIP (in the low nanomolar range) ([@B103]; [@B53]) and bind also PACAP with similar affinity, hence the name VPAC given to VIP receptors ([@B71]). The VIP receptor subfamily also includes a third receptor, PAC~1~ (PACAP specific receptor), which binds VIP with low affinity (in the micromolar range) ([@B53]). VPAC receptors exhibit multiple consensus sites for phosphorylation by intracellular kinases and *N*-glycosylation, but differences in the *N*-glycosylation are observed according to tissue and/or species ([@B71]).

Both VPAC and PAC~1~ receptors are positively coupled to G~αs~ and stimulate the cAMP/PKA signaling pathway (see [@B71]; [@B53] for review). However, PAC~1~ receptors additionally strongly stimulate G~αq~ and the phospholipase C (PLC)/PKC signaling pathway, while VPAC receptors activate it weakly ([@B52]; [@B103]). However, VPAC~1~ receptors can couple to G~i/o~ proteins in the hippocampus ([@B87]) and VIP enhancement of \[Ca^2+^\]~i~ in astrocyte cultures depends on IP~3~ turnover ([@B39]).

VIP Receptors and Hippocampal Neurotransmission {#S4}
===============================================

Although VIP and PACAP receptors have a widespread expression in the brain, VPAC~1~ receptors are predominantly found in the hippocampus and cerebral cortex, while VPAC~2~ receptors prevail in the thalamus and suprachiasmatic nucleus, showing lower expression in the hippocampus, spinal cord, dorsal root ganglia and brainstem ([@B53]; [@B11]). Not surprisingly, VIP and VIP receptors are involved in learning and memory processes ([@B103]; [@B11]), yet, elucidating the differential involvement of each VIP receptor in the actions of VIP has proven very difficult until ligands with enough selectivity to discriminate between VPAC~1~ and the VPAC~2~ receptor were developed ([@B46],[@B47],[@B48]; [@B79]). This is particularly important in the hippocampus, where both receptors are expressed ([@B98]; [@B62]).

VIP receptors are unevenly distributed in different hippocampal layers. VPAC~2~ receptors are more expressed in *SP* of the Ammon's Horn implying a key role in the modulation of hippocampal pyramidal cell activity, whereas VPAC~1~ receptors are preferentially located in the *SO* and *SR* and partially co-localized with glial markers ([@B1]; [@B62]). No study has to date identified VPAC~1~ receptors in hippocampal interneurons, yet the fact that VIP enhancement of synaptic transmission to CA1 pyramidal cells involves inhibition of GABAergic interneurons that control pyramidal cell dendrites, leading to disinhibition ([@B29]), an action mediated by activation of VPAC~1~ receptors ([@B26]) preferentially located in the *SO*, *SR* or *O/A* ([@B98]; [@B62]) suggests VPAC~1~ receptors are in fact responsible for VIP actions on hippocampal interneurons. VPAC~2~ receptors are the main mediators of VIP enhancement of pyramidal cell excitability ([@B27]), and likely mediators of VIP enhancement of NMDA receptor currents in pyramidal cells ([@B104]), effects that are mostly post-synaptic and independent of GABAergic transmission ([@B16]; [@B29]), and that likely involve inhibition of the sAHP ([@B50]) (see [Table 1](#T1){ref-type="table"}).

VIP modulation of hippocampal GABAergic transmission involves both presynaptic enhancement of GABA release and postsynaptic facilitation of GABAergic currents in interneurons ([@B100]; [@B29]). We recently reported a dual opposing regulation of GABA release by VPAC receptors in isolated hippocampal nerve terminals ([@B25]): VPAC~1~ receptors inhibit and VPAC~2~ receptors enhance GABA release. VPAC~1~ receptor activation inhibits voltage-gated calcium channel (VGCC)-dependent GABA exocytosis through a G~i/o~ and PKA-independent and partially PKC-dependent mechanism ([@B25]). VPAC~2~ receptor activation enhances VGCC-dependent GABA exocytosis by a G~s~/PKA/PKC-dependent mechanism but also enhances GAT-1 carrier-mediated GABA outflow through a G~s~/PKC-dependent mechanism. Given the asymmetry in VPAC~1~ and VPAC~2~ receptor location in different layers of Ammon's horn, VIP may differentially modulate GABA release to pyramidal cells and *INs*, and thus have distinct consequences on synaptic transmission to pyramidal cell dendrites and pyramidal cell activity, suggesting several possible therapeutic applications.

VIP and Synaptic Plasticity {#S5}
===========================

Synaptic plasticity relies on long-lasting, activity-dependent bidirectional changes in the strength of synaptic communication leading to long-term potentiation (LTP) and long-term depression (LTD) ([@B77]) and is widely accepted as the cellular mechanism underlying memory storage ([@B10]). LTP can be triggered by a single episode of high frequency stimulations (HFS), such as a tetanus or theta burst ([@B4]; [@B72]; [@B10]), mimicking the firing of hippocampal principal cells during learning tasks, and was the first synaptic plasticity mode to be associated with hippocampal-dependent memory formation ([@B10]). LTD can be elicited by low-frequency stimulation (LFS), mimicking hippocampal activity during delta waves, and is involved in hippocampal-dependent memory processes associated with behavioral flexibility like memory extinction, reversal learning, reformulation of previously formed memories, terminating/shifting attention and in stabilizing the effects of learning ([@B65]; [@B4]; [@B63]; [@B19]). Both LTP and LTD require the activation of NMDA receptors, and their stability or long-lasting expression is dependent on subsequent activation of multiple intracellular cascades ([@B19]; [@B10]). LTP of glutamatergic transmission requires activation of Ca^2+^/calmodulin-dependent protein kinase II (CaMKII) and recruitment and insertion of AMPA receptors into the postsynaptic membrane (early-LTP) ([@B81]; [@B8]). Endurance and stability of LTP is believed to require synaptic contact enlargement and both PKA activity and *de novo* protein synthesis (late-LTP) ([@B81]; [@B10]).

Recent evidence supports the view that disinhibition plays a crucial role in regulating hippocampal synaptic plasticity ([@B5]). Furthermore, [@B104] showed that exogenously applied VIP enhances NMDA currents in CA1 pyramidal cells, an effect mimicked by VPAC~2~ and to a lesser extent by VPAC~1~ selective agonists. This suggests that either endogenous VIP or PACAP, the two endogenous agonists of this receptor, could contribute to NMDA-dependent hippocampal synaptic plasticity such as LTP, LTD and depotentiation. We recently described that endogenous VIP, through VPAC~1~ receptor activation, modulates the NMDA receptor-dependent LTD and depotentiation in the CA1 area of the hippocampus ([@B23]). Furthermore, disinhibition achieved through inhibition of VPAC~1~ receptors was more efficient than blockade of GABA~A~--mediated transmission in revealing LTD, suggesting that *SR* interneurons are fundamental in restraining synaptic adaptations underlying expression of LTD. VPAC~1~ receptor activation by endogenous VIP also enhances hippocampal LTP induced by TBS, an action that is dependent on GABAergic transmission and involves phosphorylation of GluA1 AMPA subunit by CamKII, a fundamental mechanism for receptor synaptic recruitment ([@B28]; [@B13]; [@B24]) (see [Table 1](#T1){ref-type="table"}). Activation of hippocampal VPAC~2~ (but not VPAC~1~) receptors also promotes phosphorylation of GluA1 at Ser845 ([@B94]), a PKA target site that is implicated in LTP maintenance and late-LTP ([@B8]).

VIP and PACAP modulation of hippocampal principal cell activity targets (directly or indirectly) both the dendritic and somatic compartments implicating these peptides in regulation of both Hebbian and homeostatic plasticity ([@B101]; [@B106]; [@B41]), yet the physiological and behaviorally relevant stimuli for this modulation are still largely uncovered. Recently, it was described that *VIP*^+^ *IS INs* are activated by both Schaffer collateral and commissural excitatory fibers, being recruited fundamentally during theta oscillations but not during fast ripples ([@B75]), suggesting a fundamental role in information gating during spatial navigation and memory encoding. Accordingly, *VIP*^+^ *IS INs* are targeted by *medium raphe* serotonergic and GABAergic projections and septal cholinergic fibers, fundamental for the pacing, engagement and suppression of hippocampal theta rhythm ([@B99]; [@B12]; [@B97]).

Release of large dense core vesicles containing neuropeptides is known to require high-intensity repetitive stimulation, unlike release of small synaptic vesicles containing fast transmitters such as glutamate or GABA ([@B43]). Firing of VIP-containing interneurons locked with theta rhythm may suffice to release endogenous VIP from hippocampal nerve terminals.

VIP in Cognitive Processes {#S6}
==========================

Early from its discovery, VIP was described to have a crucial role in mnemonic processes and particularly in hippocampal-dependent memory traits. In particular, endogenous VIP was implicated in spatial learning in the Morris water maze ([@B45]; [@B90]; [@B57]), avoidance learning in the T-maze ([@B40]) or the shuttle box, together with reduced rearing exploratory behavior ([@B21]; [@B91]), suggesting that VIP is mainly involved in regulating motivated learning behavior. VIP has lateralized effects on the modulation of exploratory behavior and passive avoidance learning ([@B60], [@B61]) and anxiolytic and anti-depressive effects ([@B59]), and rescues deficits in hippocampal-dependent passive avoidance learning tasks in a rat model of depression. Recently, VIP-mediated hippocampal disinhibition of pyramidal cell activity was shown to play a crucial role in goal-directed spatial learning tasks ([@B95]).

VIP-KO mice show decreased expression of VPAC~2~ and to a lesser extent VPAC~1~ receptors together with strong circadian rhythm disruption and enhanced arousal and hyperactivity in the open-field test ([@B44]). Furthermore, VIP-deficient mice shows impaired recall and reversal learning in a fear conditioning test and deficits in social behavior ([@B15]; [@B89]). VPAC~2~-KO mice display normal acquisition of fear conditioning, contextual and cued fear memory, but impaired extinction of cued fear memory ([@B3]).

VIP participates in the pathophysiology of several neurological disorders associated with cognitive disfunction, like depression ([@B58]), autism spectrum disorders, Alzheimer's disease (AD), Parkinson's disease (PD) and epilepsy ([@B31]; [@B56]; [@B102]). Due to its anti-apoptotic, anti-inflammatory and neuroprotective actions, VIP and its receptors constitute promising therapeutic targets in many of these pathologies ([@B49]; [@B32]; [@B107]).

VIP, Seizures, and Epilepsy {#S7}
===========================

Epilepsy is the most common, chronic neurological disease ([@B34]) and is characterized by the incidence of recurrent, unprovoked seizures with associated cognitive, psychological and social disturbances ([@B18]; [@B34]). According to its underlying causes epilepsy is classified into genetic or idiopathic. More than 500 genes are associated with predisposition to develop epilepsy ([@B34]). Idiopathic epilepsy, has unknown causes but often follows several possible precipitating events such as head trauma, stroke, brain hypoxia, infectious/autoimmune diseases, tumors or childhood febrile seizures ([@B18]).

Mesial temporal-lobe epilepsy with hippocampal sclerosis (MTLE-HS), the most prevalent form of symptomatic focal epilepsy, is a heavy burden for the healthcare system. Many MTLE-HS patients are refractory to treatment with multiple anti-epileptic drugs, and amygdalohippocampectomy surgery is the last intervention to prevent complex partial seizures ([@B70]). Declarative memory deficits ([@B55]) are also a hallmark of MTLE-HS, that can be further aggravated by hippocampal removal. Most MTLE cases are idiopathic and evidence suggests that precipitating events trigger epileptogenesis by generating aberrant synaptic plasticity/neuronal excitability, excitotoxicity, secondary non-convulsive *status epilepticus*, inflammation and generation of reactive oxygen species (ROS) ([@B34]; [@B82]), ultimately leading to occurrence of spontaneous recurrent seizures. MTLE-HS is characterized by hippocampal sclerosis, massive neuronal loss and severe astrogliosis ([@B93]). Enhanced neurogenesis initially drives formation of new neural pathways in epileptogenesis ([@B7]), but is impaired in MTLE-HS chronic phase ([@B108]). Impaired LTP, due to pathological saturation ([@B6]), is a major cause for cognitive impairment in MTLE-HS, but changes in input/output neuronal electrical properties ([@B36]) and inhibitory/excitatory balance also occur from early in epileptogenesis ([@B37]). New drug targets able to control seizures or preventing epileptogenesis are an urgent need ([@B18]).

Neuropeptides, such as VIP, are stored in large dense-core granules and are released during the sustained high-frequency activity (5--40 Hz) occurring during epileptiform activity, being implicated in regulation of seizure susceptibility, constituting appealing targets for the development of new AEDs, potentially less susceptible to side-effects ([@B18]).

VIP is an important regulator of hippocampal activity through both direct actions on pyramidal cell excitability ([@B50]) and by regulating synaptic transmission and synaptic plasticity to pyramidal cell dendrites through disinhibition ([@B29], [@B28], [@B23]; [@B24]; [@B75]), actions that have a major impact on hippocampal-dependent learning and memory formation ([@B95]).

In human MTLE-HS, an up-regulation in VIP receptors in the seizure focus (hippocampus) was linked to the loss of principal neurons (i.e., granule cells and pyramidal neurons) without changes in the pattern and distribution of *VIP*^+^ *INs* ([@B31]). Accordingly, an enhancement in *VIP*^+^ *INs* has been described in a mouse model of temporal lobe epilepsy (TLE) ([@B64]) and decreased dendritic but not somatic GABAergic inhibition has been implicated in different animal models of experimental TLE ([@B88]; [@B20]). Although an enhancement in disinhibition caused by VIP could be implicated in reduced seizure threshold in MTLE-HS, enhancement in VIP expression is more likely a compensatory mechanism for the selective loss of OLM interneurons in TLE, the main targets of *VIP^+^ IS O/A INs*. Recently, it was described that while the overall density of the *VIP^+^ IS O/A INs* was preserved, the number of their synaptic contacts in CA1 *O/A* was reduced in the pilocarpine model of TLE and was accompanied by significant alterations in their dendritic morphology and passive membrane properties ([@B30]).

Following kainic acid and pentylenetetrazole-induced seizures in rodents, an early short-term decrease in hippocampal VIP levels following the initial (precipitating) seizures was described ([@B76]; [@B83]), suggesting that transient changes in VIP expression either contribute or counteract selective interneuron loss and plasticity changes during latent-period epileptogenesis. Preliminary studies *in vitro* show that changes in synaptic plasticity and synaptic plasticity markers following brief insults like hypoxia, bicuculine-induced seizures or inter-ictal like activity are either prevented or enhanced by a VPAC~1~ receptor antagonist, suggesting that different epileptogenic events are differentially regulated by VPAC~1~ receptor activity ([@B22]; [@B14]).

In MTLE patients, the up-regulation of VIP receptors observed chronically is consistent with an increase in surviving neurons and levels of reactive glia ([@B31]; [@B18]), suggesting that VPAC receptors (especially VPAC~1~) are promising targets for preventing epileptogenesis, a process that extends beyond the initial latent period ([@B34]). Given their role in the control of hippocampal synaptic plasticity they constitute also excellent candidates for prevention or attenuation of cognitive decline in MTLE. Furthermore, the dual role of VPAC~1~ and VPAC~2~ receptors in the control of hippocampal GABA release makes them the perfect targets for development of drugs aiming to control the imbalance in GABAergic and glutamatergic transmission associated with TLE ([@B86]; [@B25]).

Concluding Remarks {#S8}
==================

In conclusion, the importance of VIP, acting through VPAC~1~ or VPAC~2~ Rs, either to the control of hippocampal disinhibition leading to enhanced synaptic transmission or promoting a direct enhancement of pyramidal cell excitability suggests that VIP can have a differential impact in hippocampal-dependent cognition, and its possible therapeutic applications should be explored. The up-regulation of VIP receptors observed in MTLE patients and the finding obtained in animal models that the interneuron targets of VIP-containing interneurons are particularly susceptible to epileptic damage, suggest that VPAC receptors (especially VPAC~1~) are promising targets for epileptogenesis prevention and for prevention or attenuation of cognitive decline in MTLE.
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